An Educational Course on Translating Research into Drugs
Presented by the Alzheimer’s Drug Discovery Foundation
15-17 May 2016 • Budapest, Hungary


All sessions will be held at the Danubius Health Spa Resort Margitsziget. The conference has blocked off rooms for attendees at a discounted rate, please use the link above for access or visit the venue/accommodations page for more information.

Keep up to date with program and speaker updates at our mobile app accessible from http://my.yapp.us/ADDFE

Sunday, 15 May, 2016
14:00 - 17:15Registration
16:00 - 16:20Welcome & Opening Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
16:20 - 17:05Opening Plenary: Development of Human-Derived Antibodies for Neurodegenerative Proteinopathies
Jan Grimm, PhD—Neurimmune
17:05 - 17:15Q&A
17:15 - 19:00Welcoming Reception
Monday, 16 May, 2016
7:30am - 17:00pmRegistration Opens & Closes
8:30 - 9:00Opening Remarks: Challenges and Opportunities in Academic Drug Discovery
Howard Fillit, MD—Alzheimer's Drug Discovery Foundation
I. Embarking on a Drug Discovery Campaign
Chair: Luc Buée, PhD—University of Lille
9:00 - 9:05Session Overview:
Luc Buée, PhD—University of Lille
9:05 - 9:25Assembling the Right Interdisciplinary Team From the Beginning
Luc Buée, PhD—University of Lille
9:25 - 9:35Q&A
9:35 - 9:55Optimizing Target ID and Validation
Erich Wanker, PhD—The Max Delbrück Center for Molecular Medicine
9:55 - 10:05Q&A
10:05 - 10:25Assay Development/Screening
Benoit Deprez, PhD—APTEΞUS
10:25 - 10:35Q&A
II. Medicinal Chemistry Basics
Chair: Paolo Pevarello, PhD—Axxam SpA
11:05 - 11:10Session Overview:
Paolo Pevarello, PhD—Axxam SpA
11:10 - 11:30MedChem Tools for the Discovery of New Compounds Against Neuroinflammation
Alexander Dömling, PhD—University of Groningen
11:30 - 11:40Q&A
11:40 - 12:00pmMedChem Tools and Practice: Planning for Hit to Lead Progression
Paolo Pevarello, PhD—Axxam SpA
12:00pm - 12:10Q&A
12:10 - 12:30Dealing with Bioactivation: An FPR2 Story
Olivier Corminboeuf, PhD—Actelion Pharmaceuticals Ltd.
12:30 - 12:40Q&A
12:40 - 13:40LUNCH
III. Drug Discovery: From Lead to Clinical Candidate
Chair: Tamara Maes, PhD—Oryzon Genomics S.A
13:40 - 13:45Session Overview:
Tamara Maes, PhD—Oryzon Genomics S.A
13:45 - 14:05PK/PD in Preclinical Development
Hans-Ulrich Demuth, PhD—Fraunhofer IZI-MWT
14:05 - 14:15Q&A
14:15 - 14:35In Vivo Efficacy Animal Studies
Emer Leahy, PhD—PsychoGenics
14:35 - 14:45Q&A
15:10 - 15:30Formulation and Delivery
Emanuela Del Vesco—Aptuit
15:30 - 15:40Q&A
15:40 - 16:00Requirements for an IND/Working with the EMA Throughout the Drug Development Process
Allan Green, MD, PhD, JD—Boston College School of Law
16:00- 16:10Q&A
16:10 - 17:00ADDF Roundtable Session
Moderator: Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
Topics may include:
• What funding and training opportunities are available at European academic centers
• Learning from public-private initiatives, like EPAD
• Identifying European VC and angel networks
• What are some of the evolving resources at academic centers and CROs
• How are regulatory agenicies, like the EMA, facilitating drug development for neurodegenerative diseases
17:00 - 18:30Networking Reception
Tuesday, 17 May, 2016
7:30am - 14:45pmRegistration Opens and Closes
8:30 - 8:35Welcome & Opening Remarks
Manfred Windisch, PhD— NeuroScios GmbH
8:35 - 9:05Opening Plenary: Machine Learning in Drug Discovery
Mati Karelson, PhD—University of Tartu
9:05 - 9:15Q&A
IV. Strategies for Challenging CNS Targets—Case Study Examples
Chair: Manfred Windisch, PhD—NeuroScios GmbH
9:15 - 9:20Session Overview:
Manfred Windisch, PhD—NeuroScios GmbH
9:20 - 9:40Case Study One: Overcoming the Blood-Brain Barrier—The Extra Challenge for CNS Drug Development
Georg Terstappen, PhD—AbbVie
9:40 - 9:50Q&A
9:50 - 10:10Case Study Two – Development of Pre-Clinical Candidates for Neurodegenerative Diseases
Marie-Louise Jung, PhD—Prestwick Chemical
10:10 - 10:20Q&A
11:00 - 11:20Case Study Three – Lead Candidate to IND
Hermann Mucke, PhD—H. M. Pharma Consultancy
11:20 - 11:30Q&A
11:30 - 11:50Case Study Four – Considerations for Developing Biomarkers
Tamara Maes, PhD—Oryzon Genomics S.A
11:50am - 12:00pmQ&A
V. Commercialization Strategies: Developing Science into Products
Chair: Dirk Beher, PhD—Asceneuron SA
13:00 - 13:05Session Overview:
Dirk Beher, PhD—Asceneuron SA
13:05 - 13:25IP Considerations and Technology Transfer
Neus Virgili, BSc—Oryzon Genomics S.A
13:25 - 13:35Q&A
13:35 - 13:55Founding and Funding a Company—From an Academic or Biotech Perspective
Dirk Beher, PhD—Asceneuron SA
13:55 - 14:05Q&A
14:05 - 14:25Dementia Discovery Fund: A New Collaborative Approach to Major Unmet Medical Needs
Carol Routledge, PhD—SV Life Sciences
14:25 - 14:35Q&A
14:35 - 14:45Closing Remarks:
Howard Fillit, MD—Alzheimer's Drug Discovery Foundation